GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (OTCPK:LVCLY) » Definitions » ROC %

Algorae Pharmaceuticals (Algorae Pharmaceuticals) ROC % : -6,590.16% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Algorae Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Algorae Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was -6,590.16%.

As of today (2024-05-15), Algorae Pharmaceuticals's WACC % is 6.27%. Algorae Pharmaceuticals's ROC % is -5898.31% (calculated using TTM income statement data). Algorae Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Algorae Pharmaceuticals ROC % Historical Data

The historical data trend for Algorae Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals ROC % Chart

Algorae Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -780.94 -525.53 -700.69 -2,314.98 -3,917.81

Algorae Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,051.49 -6,600.76 -6,436.36 -3,666.67 -6,590.16

Algorae Pharmaceuticals ROC % Calculation

Algorae Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=-1.43 * ( 1 - 0% )/( (0.034 + 0.039)/ 2 )
=-1.43/0.0365
=-3,917.81 %

where

Algorae Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-2.01 * ( 1 - 0% )/( (0.039 + 0.022)/ 2 )
=-2.01/0.0305
=-6,590.16 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals  (OTCPK:LVCLY) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Algorae Pharmaceuticals's WACC % is 6.27%. Algorae Pharmaceuticals's ROC % is -5898.31% (calculated using TTM income statement data). Algorae Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Algorae Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals (Algorae Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (Algorae Pharmaceuticals) Headlines